F. Stephen Hodi

F. Stephen Hodi a Director of the Melanoma Center and the Center for Immuno-oncology at Dana-Farber/Brigham and Women’s Cancer Center and Professor of Medicine at Harvard Medical School. He was a recognized leader in the development of immune therapy and melanoma therapeutics; known for leadership in research and clinical development of checkpoint inhibitors. His clinical interests in gene therapy for cancer, melanoma research, and tumor immunology; he was the lead researcher on the study that resulted in the FDA approval of ipilimumab. F. Stephen is also Chair of Bicara’s Clinical Advisory Board. He holds an M.D. from the Weill Medical College of Cornell University; an Internal Medicine residency at the University of Pennsylvania School of Medicine; a Medical Oncology fellowship at the Dana-Farber Cancer Institute.